ReviewJournal of intensive medicine2025
High-flow nasal oxygen is the reference treatment in acute hypoxemic respiratory failure: Pro.
Review in Journal of intensive medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In patients with hypoxemic acute respiratory failure (ARF), the first-line treatment is oxygen therapy, which may include the administration of high-flow nasal oxygen (HFNO), noninvasive ventilation (NIV), or continuous positive airway pressure (CPAP). In addition to improving oxygenation, HFNO and NIV reduce the work of breathing as compared to standard oxygen, while CPAP does not. However, tolerance to NIV and CPAP is clinically challenging, resulting in treatment interruption in 10 %-20 % of cases. Compared to standard oxygen, HFNO has been shown to reduce the risk of intubation, while the benefits of NIV or CPAP, even when delivered via a helmet, require further evaluation. Although evidence for the efficacy of HFNO in reducing mortality remains inconclusive, HFNO has emerged as the reference treatment and is recommended for patients with hypoxemic ARF given its benefit in reducing the risk of intubation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.